Mycosis fungoides (MF) and its variants represent the most common forms of cutaneous T-cell lymphomas. The term MF is restricted to the classical form characterized by the slow progression of patches,...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on mycosis fungoides is limited due to its rarity and the lack of systematic clinical studies. As a form of cutaneous T-cell lymphoma, it affects a relatively small number of individuals, making large-scale research challenging. Additionally, the clinical features may overlap with other skin conditions, complicating the characterization of MF.
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
There are several orphan drugs designated for mycosis fungoides, including human anti-CD4 monoclonal antibody, MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p, and Methotrexate with laurocapram, although none are currently FDA-approved. Brentuximab vedotin and meclorethamine are approved treatments. There is one active clinical trial available for MF. You can find more information about ongoing studies at https://clinicaltrials.gov/search?cond=mycosis%20fungoides%20and%20variants.
Actionable guidance for navigating care for mycosis fungoides and variants
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on mycosis fungoides is limited due to its rarity and the lack of systematic clinical studies. As a form of cutaneous T-cell lymphoma, it affects a relatively small number of individuals, making large-scale research challenging. Additionally, the clinical features may overlap with other skin conditions, complicating the characterization of MF.
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
There are several orphan drugs designated for mycosis fungoides, including human anti-CD4 monoclonal antibody, MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p, and Methotrexate with laurocapram, although none are currently FDA-approved. Brentuximab vedotin and meclorethamine are approved treatments. There is one active clinical trial available for MF. You can find more information about ongoing studies at https://clinicaltrials.gov/search?cond=mycosis%20fungoides%20and%20variants.
Actionable guidance for navigating care for mycosis fungoides and variants
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on mycosis fungoides is limited due to its rarity and the lack of systematic clinical studies. As a form of cutaneous T-cell lymphoma, it affects a relatively small number of individuals, making large-scale research challenging. Additionally, the clinical features may overlap with other skin conditions, complicating the characterization of MF.
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
There are several orphan drugs designated for mycosis fungoides, including human anti-CD4 monoclonal antibody, MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p, and Methotrexate with laurocapram, although none are currently FDA-approved. Brentuximab vedotin and meclorethamine are approved treatments. There is one active clinical trial available for MF. You can find more information about ongoing studies at https://clinicaltrials.gov/search?cond=mycosis%20fungoides%20and%20variants.
Actionable guidance for navigating care for mycosis fungoides and variants
To navigate mycosis fungoides, consider consulting a dermatologist with expertise in cutaneous lymphomas. This specialist can provide tailored care and management strategies. Additionally, the National Organization for Rare Disorders (NORD) offers resources at rarediseases.org. While no patient organizations are currently identified, participating in clinical trials can provide access to experimental treatments and contribute to research. Keep an eye on clinical trials for potential opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning mycosis fungoides and variants
Updated Feb 9, 2026
A case series explores the management of mycosis fungoides using chlormethine hydrochloride gel alongside systemic therapies. The findings contribute to understanding treatment combinations for this rare skin lymphoma.
A phase 2 trial evaluated resminostat as a maintenance treatment for patients with advanced-stage mycosis fungoides or Sézary syndrome. The study was multicenter, double-blind, and randomized, providing insights into the drug's efficacy in this rare skin lymphoma.